NEWS

Press Releases AND Media
In the News

Attralus Eyes Further Work on Therapeutic Candidates with New Funding

www.biospace.com
Source Author:

Krystle Vermes

September 14, 2020
PDF Version
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free

California-based biopharmaceutical company Attralus announced today that it has concluded a $25 million Series A financing round. With this funding, Attralus will be able to conduct further work on its pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain) and potentially ALECT2 systemic amyloidosis.

Systemic amyloidosis translates into about 30 different disorders that occur in the body as a result of protein misfolding. This produces amyloid fibrils that accumulate in various organs.

California-based biopharmaceutical company Attralus announced today that it has concluded a $25 million Series A financing round. With this funding, Attralus will be able to conduct further work on its pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain) and potentially ALECT2 systemic amyloidosis.

Systemic amyloidosis translates into about 30 different disorders that occur in the body as a result of protein misfolding. This produces amyloid fibrils that accumulate in various organs.

<< Back to All News

our apologies

TABLET & MOBILE EXPERIENCES
ARE STILL UNDER CONSTRUCTION

Please view on a desktop or laptop computer.